ERBB2 and breast carcinoma: Trastuzumab (Herceptin), a monoclonal antibody that interferes with HER2 signalling, has improved clinical outcome in patients with HER2-positive breast cancers [4, 5], however it is apparent that up to 66% of patients exhibit resistance to trastuzumab monotherapy [4, 5].